8-KLeadership Changes

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Feb 5, 2008)

Filed February 5, 2008For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K report on February 4, 2008, detailing compensation arrangements for its named executive officers as of January 30, 2008. The report outlines the 2007 bonus awards and 2008 base salaries, reflecting the company's performance and individual contributions. Notably, the report also discloses the grant of stock options and performance shares for the 2008 fiscal year, designed to incentivize long-term growth and alignment with shareholder interests. The performance share awards are particularly significant, as their conversion into actual shares is directly tied to Gilead's total shareholder return (TSR) and revenue growth relative to a peer group of biotech and pharmaceutical companies over a three-year period. This structure aims to ensure that executive compensation is heavily influenced by the company's ability to outperform its industry peers, a move that should be of interest to investors focused on executive accountability and long-term value creation.

Key Highlights

  • 1The Compensation Committee set 2008 base salaries and determined 2007 bonus awards for named executive officers.
  • 2John C. Martin, CEO, received a 2007 bonus of $1,617,000 and a 2008 base salary of $1,155,000.
  • 3Executive compensation is linked to both individual performance and company-wide financial and non-financial objectives.
  • 4Stock options were granted with an exercise price of $43.15, vesting over five years.
  • 5Performance shares were granted, with their conversion dependent on Gilead's Total Shareholder Return (TSR) and revenue growth relative to the AMEX Biotech-Pharmaceutical Index over a three-year period (2008-2010).
  • 6Performance shares can convert into 0% to 200% of the granted number of shares based on relative performance.
  • 7Specific provisions exist for accelerated vesting of performance shares in cases of death, disability, or change in control.

Frequently Asked Questions

The main purpose of this 8-K filing is to disclose the compensation decisions made by Gilead Sciences' Compensation Committee regarding the 2007 bonuses and 2008 base salaries for its named executive officers, as well as the granting of stock options and performance shares for the 2008 fiscal year.

Executive compensation is tied to company performance through two primary mechanisms disclosed in this filing: 1) The 2007 bonus awards were based on individual performance and the company's attainment of specific financial and non-financial objectives. 2) The conversion of performance shares granted in 2008 is directly linked to Gilead's Total Shareholder Return (TSR) and revenue growth compared to a peer group of companies over a three-year period.

The key performance metrics for the performance shares are Gilead's Total Shareholder Return (TSR) and revenue growth, measured over a three-year period (January 1, 2008, to December 31, 2010) and compared against the performance of companies in the AMEX Biotech-Pharmaceutical Index. The number of shares an executive receives can range from 0% to 200% of the granted amount based on how Gilead ranks against its peers on these two metrics.

Generally, performance shares are forfeited if the executive's continuous service terminates before the end of the performance period. However, there are provisions for accelerated vesting. If an executive dies or becomes disabled, a portion of the shares may vest based on service completed. In the event of a change in control, performance shares can immediately convert into vested shares, either at 100% of the grant or based on performance over an abbreviated period, depending on the timing of the transaction.